Oral Administration Afforded by CDK2 Inhibitors May Ease the Price of Admission in Platinum-Resistant Ovarian Cancer

June 16, 2026

Caroline Seymour

Premal Thaker, MD, MS, discusses the role for CDK2 inhibition in platinum-resistant ovarian cancer.

Roswell Park Recognized by National Foundation for Cancer Prevention and Early Detection Efforts

June 16, 2026

Roswell Park Comprehensive Cancer Center

Roswell Park Comprehensive Cancer Center launched a phase 2 trial evaluating SurVaxM plus temozolomide in progressing neuroendocrine tumors.

Lutetium Lu 177 Vipivotide Tetraxetan Provides rPFS Benefit in mHSPC Regardless of Disease Volume or De Novo/Recurrent Status

June 16, 2026

Kyle Doherty

Fred Saad, MD, CQ, FRCS, FCAHS, discusses data from subgroup analyses of the PSMAddition trial by disease volume and in de novo/recurrent mHSPC.

Experts Weigh In on Some of the Most Impactful Data in Melanoma From ASCO 2026

June 16, 2026

Caroline Seymour

Ashling Wahner ,

Experts unpack key melanoma data shared during the 2026 ASCO Annual Meeting.

Emiltatug Ledadotin Elicits Responses in Aggressive Adenoid Cystic Carcinoma

June 16, 2026

OncLive Staff

Emi-Le generated durable responses and encouraging PFS with manageable safety in patients with aggressive adenoid cystic carcinoma.

Tacabrutideg Is Tolerable and Shows Efficacy Signals Across BTK Inhibitor–Naive CLL and Other B-Cell Malignancies

June 16, 2026

Ashling Wahner

Tacabrutideg's safety profile was tolerable, and the drug had antitumor activity in BTK inhibitor–naive patients with CLL/SLL and other B-cell malignancies.

In Vivo CD19/CD20 CAR T-Cell Therapy Is Safe, Yields 100% ORR at Phase 1, Dose Level 2 in R/R Non-Hodgkin Lymphomas

June 15, 2026

Chris Ryan

LB2501, an off-the-shelf in vivo dual-target CAR T-cell therapy, produced a 100% ORR at dose level 2 across DLBCL, MCL, and follicular lymphoma.

Zanubrutinib Displays Durable Long-Term Efficacy, Safety in Older Treatment-Naive CLL/SLL

June 15, 2026

OncLive Staff

Zanubrutinib yielded sustained progression-free survival and a tolerable safety profile in older patients with CLL/SLL treated in the SEQUOIA trial.

Subcutaneous Blinatumomab Yields High Efficacy Rates in R/R Ph+ B-ALL

June 15, 2026

Ashling Wahner

Treatment with subcutaneous blinatumomab generated high CR rates across 2 dosing regimens in pretreated, relapsed/refractory, Ph-positive B-ALL.

Real-World Analysis Reveals Liso-Cel Elicits High Response Rates in R/R Mantle Cell Lymphoma

June 15, 2026

OncLive Staff

Real-world data show liso-cel drives high response rates and durable benefit in relapsed/refractory MCL, including high-risk patients.

Rocbrutinib Shows Durable Efficacy in BTK Inhibitor–Pretreated R/R Mantle Cell Lymphoma

June 15, 2026

OncLive Staff

Rocbrutinib delivered durable responses and encouraging survival with manageable safety in BTK inhibitor–pretreated relapsed/refractory MCL.

ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma

June 15, 2026

Dana-Farber Cancer Institute

Dana-Farber investigators presented encouraging positive results from the phase 2 ImmunoPRISM trial in smoldering myeloma.

Optune Pax Lays the Foundation for Future TTField Development in Locally Advanced Pancreatic Cancer

June 15, 2026

Courtney Flaherty

Vincent Picozzi, MD, discusses the PANOVA-3 data supporting the approval of Optune Pax and the future of TTFields in pancreatic cancer.

FDA Accepts BLA for Ozekibart in Conventional Chondrosarcoma

June 15, 2026

Courtney Flaherty

The FDA has accepted a BLA for ozekibart in unresectable or metastatic conventional chondrosarcoma, setting a PDUFA goal date of April 14, 2027.

Oral Selective Estrogen Receptor Degraders in HR-Positive/HER2- Negative Metastatic Breast Cancer: Clinical Insights on Sequencing, Biomarkers, and Emerging Combinations

June 15, 2026

Learn how ESR1 mutations drive endocrine resistance and how FDA-approved oral SERDs improve outcomes, shaping smarter sequencing and future combos.